氟尿嘧啶联合西多福韦术后治疗成人喉乳头状瘤临床疗效观察

Effect of fluorouracil combined with cidofovir in treatment of adult patients with laryngeal papilloma

目的探讨氟尿嘧啶联合西多福韦术后治疗成人喉乳头状瘤的临床治疗效果。方法 68例行支撑喉镜下手术切除术喉乳头状瘤患者术后分为观察组和对照组,每组34例。对照组患者给予人白细胞干扰素肌肉注射治疗12个月;观察组患者给予氟尿嘧啶联合西多福韦病灶注射治疗12个月,比较2组治疗效果。结果 2组患者治疗后临床症状均显著改善(P<0.05);与对照组比较,观察组患者症状改善更显著(P<0.05)。观察组患者喉乳头状瘤复发率、复发时间及癌变率分别为26.5%(9/34)、(309.7±12.2)d、8.8%(3/34),对照组患者喉乳头状瘤复发率、复发时间及癌变率分别为47.1%(16/34)、(108.5±7.8)d、20.6%(7/34);观察组患者喉乳头状瘤复发率和癌变率显著低于对照组(P<0.05),复发时间较对照组显著延长(P<0.05)。结论氟尿嘧啶联合西多福韦术后治疗成人喉乳头状瘤可显著降低肿瘤复发率、癌变率,延迟肿瘤复发。

Objective To investigate the clinical effect of fluorouracil combined with cidofovir in the treatment of adult patients with laryngeal papilloma. Methods A total of 68 patients with laryngeal papilloma were divided into observation group and control group after operation by laryngoscope, with 34 patients in each group. The patients in control group were trea- ted with human leukocyte interferon by intramuscular injection for 12 months. The patients in observation group were treated with fluorouracil and cidofovir by intralesional injection for 12 months. The clinical effect was compared between the two groups. Results The clinical symptoms of patients improved significantly in the two groups （ P 〈 0.05 ）, but the improvement was more in observation group（ P 〈 0.05 ）. The recurrence rate, recurrence time and canceration rate of laryngeal papilloma in observation group was 26.5 % （ 9/34 ）, （ 309.7 ±12.2 ） d and 8.8 % （ 3/34 ）, respectively. The recurrence rate, recurrence time and canceration rate of laryngeal papilloma in observation group was 47.1% （16/34）, （108.5 ±7.8 ）d and 20.6% （7/34）, respectively. The recurrence rate and eaneeration rate of laryngeal papilloma in observation group were significantly lower than those in control group （ P 〈 0.05 ） , but the recurrence time prolonged significantly in observation group （ P 〈 0.05 ）. Conclusion Fluorouracil combined with cidofovir can significantly reduce the recurrence rate and canceration rate in adult patients with laryngeal papilloma, and can delay the neoplastic recurrence.